Final results from the open-label extension of the Phase III HELP study of lanadelumab-flyo as long-term prophylaxis in patients with hereditary angioedema

In patients 12 years of age and older who received treatment for a mean (SD) duration of 29.6 (8.2) months, the mean HAE attack rate was reduced by 87.4% overall versus baseline (N=212). Safety and efficacy were consistent with that observed in the main Phase III trial.

Biospace Inc.